Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Ultrasound imaging contrast enhancement” does not denote a single therapeutic target or receptor; it refers to exogenous ultrasound contrast agents—stabilized gas microbubbles administered primarily intravenously to increase echogenicity and enable contrast-enhanced ultrasound (CEUS). Clinically approved UCAs are suspensions of gas bodies (e.g., perfluorocarbon, sulfur hexafluoride, nitrogen) encapsulated by shells (lipid, albumin, or polymer). When insonated, microbubbles resonate and exhibit pronounced nonlinear oscillations that generate strong harmonic backscatter, improving blood pool visualization and enabling real-time perfusion assessment. High–mechanical index pulses can intentionally disrupt bubbles to quantify replenishment kinetics. Second-generation agents (e.g., Lumason/SonoVue, Definity/Luminity, Optison, Sonazoid) differ by gas core and shell, which affect stability, circulation time, and, for Sonazoid, Kupffer-cell uptake enabling postvascular liver phase imaging. Approved indications include left ventricular opacification/endocardial border delineation, focal liver lesion characterization, pediatric vesicoureteral reflux assessment, and fallopian tube patency; additional vascular and organ applications exist outside the US and off-label. Research directions include targeted microbubbles for molecular imaging and drug/gene delivery, and emerging protein-based gas vesicles as genetically encodable acoustic reporters. Safety profiles are favorable in routine diagnostic use, though cavitation-mediated bioeffects have been described in preclinical settings and specific cardiac arrhythmias have been rarely reported with certain protocols.
Acoustic cavitation/nonlinear oscillation of intravascular microbubbles enhances backscatter; High mechanical index pulses can disrupt microbubbles for destruction–replenishment perfusion imaging; Targeted microbubbles bind vascular biomarkers to localize signal (research/adjunct)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ultrasound contrast agent (microbubble) (UCA).